Company ProfilePremium

Denka Company Limited

Company Profile Analysis

Ticker: 4061.Tデンカ株式会社

ESOMAR 23 Corporate BadgeISO Certifications Badge
Denka Company Limited - Company showcase

Year Founded & Workforce

1915

6,358 Employees

Denka Company Limited logo

Denka Company Limited Employee Contacts

4 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Denka Company Limited Overview

Denka is a 111-year-old, mid-cap Japanese specialty and commodity chemical maker. It is moving from carbide-derived commodity chemistry toward high-value inorganic and organic materials for AI semiconductors and power infrastructure, plus a healthcare franchise in vaccines and diagnostics. Its competitive core is powder and particle engineering:

  • spherical fused silica and spherical alumina fillers for advanced semiconductor packaging;

  • acetylene black for high-voltage cables and energy storage;

  • ALSINK and silicon-nitride heat-dissipation materials for power modules;

  • the newly commercialised SNECTON low-dielectric resin for AI server substrates.

These growth franchises are tied to legacy businesses that are cyclical or structurally challenged: chloroprene rubber, styrenics and special cement additives. Those legacy businesses drove a 2023–2025 earnings collapse, including a ¥12.3bn net loss in FY3/25 caused by the US DPE chloroprene plant. Under CEO Ikuo Ishida, the "Mission 2030 Phase 2" plan (FY3/27–FY3/29) aims to:

  • rebuild earning power to record operating income;

  • reach ROE of at least 8%;

  • exit DPE;

  • prepare a spin-off of the styrene business by April 2027.


Company's own description

The FY3/26 Annual Securities Report says the group's main business is manufacturing and selling products in four reportable segments, plus related services (plant engineering and trading in "Others"):

  • Electronics & Innovative Products (E&I)

  • Life Innovation (LI)

  • Elastomers & Infrastructure Solutions (E&IS)

  • Polymer Solutions (PS)

The company's stated corporate Purpose under Mission 2030 is to "Make the world a better place as specialists in chemistry" (Mission 2030 Phase 2 notice, 27 Feb 2026).

Independent characterisation

Denka is a vertically integrated, manufacturing-led materials company. Its revenue is almost entirely product sales; there are no meaningful subscription or licensing revenues. Its origins in hydro-powered calcium carbide production at the Omi Plant (Itoigawa, Niigata) explain its unusual combination of businesses:

  • the acetylene chain: carbide → acetylene → acetylene black and chloroprene;

  • inorganic high-temperature processing: fused silica, alumina, nitrides;

  • a separate petrochemical chain based on naphtha-derived styrene at the Chiba Plant;

  • a biologics and diagnostics business inherited from Denka Seiken, absorbed in April 2020.

Revenue model mix (analyst estimate from segment structure):

  • More than 98% product sales, about 2% engineering services (in "Others"). The company does not disclose this mix.

  • In Life Innovation, influenza vaccines are sold mainly under Japanese public-health procurement channels. Diagnostic kits are sold through distributors to clinics and hospitals.

  • In E&I, products are qualified by customers ("spec-in"), so revenue is sticky once a material is designed into a substrate or package.

  • In PS and E&IS, prices are commodity-linked. Many contracts include raw-material pass-through formulae, which create inventory-valuation timing effects (Q1 FY3/27 inventory gain of +¥6.0bn).

Value-chain position:

Mid-stream supplier of engineered materials: Fillers go to epoxy-molding-compound makers and copper-clad-laminate (CCL) makers. Acetylene black goes to cable compound and battery makers. Ceramic substrates go to power-module makers.

Upstream monomer and polymer producer: Styrene monomer, ABS/AS/SBC/MS resins, and chloroprene rubber.

Downstream branded healthcare products: Vaccines, rapid-antigen test kits, in-vitro diagnostic (IVD) reagents.

Customer types and end-markets (FY3/26 E&I application mix per company):

  • AI-related semiconductors and power infrastructure (high-voltage cables, energy storage systems, DC transmission) together make up a rising share of E&I sales. The company chart shows AI-related applications at about 21–24% and power infrastructure at about 11–15% of segment sales.

  • Other end-markets: general-purpose semiconductors and electronic components; xEV and automotive; electric railways.

  • Healthcare: clinics and hospitals (rapid tests), national influenza-vaccine programmes, laboratories (IVD and Kainos reagents).

  • Construction and infrastructure: special cement additives; corrugated pipes for agricultural and civil-engineering use.

  • Automotive and industrial rubber: chloroprene for belts, hoses, adhesives, wetsuits and medical gloves.

  • Consumer and industrial plastics: PC monitors (MS-resin light-guide plates), appliances, general merchandise, food packaging sheets and containers.

  • Wig and hairpiece fibre: Toyokalon, mainly for African markets.

  • No single customer exceeds 10% of net sales (FY3/26 Tanshin).

Strategy

Mission 2030 — evolution

The original plan (announced November 2022, covering FY3/24–FY3/31):

  • framed strategy around three themes: Business Value Creation, Human Resources Value Creation and Management Value Creation;

  • targeted FY2030 operating income of ¥100bn and ROE of 15%;

  • included an environmental investment budget of ¥85bn over 8 years.

Phase 1 (FY3/24–FY3/26) badly missed its trajectory. Management named the reasons: a slump in electronic-material demand, weak US chloroprene performance, slower-than-expected payback on EV-related investments, and higher fixed costs.

Mission 2030 Phase 2 (FY3/27–FY3/29), announced 27 February 2026

Phase 2 targets (JPY Bn)FY3/26AFY3/27 planFY3/27 guidanceFY3/28 planFY3/29 plan
Operating income26.235.030.040.045.0
Net income15.718.016.022.026.0
ROE (%)5.2—5.1—8.0

The presentation is titled "Rebuilding Earning Power: The Start of a New Growth Phase." It sets three key measures:

  1. Strengthen growth businesses in ICT & Energy and Healthcare.

  2. Turn Sustainable Living into cash cows by keeping only competitively sustainable businesses.

  3. Resolve DPE early and minimise the financial burden. A closure plan is targeted early in Phase 2.

Supporting elements:

  • Business units are reclassified as growth drivers, stable earners or cash cows.

  • Investment is tightly selected to restore the balance sheet.

  • At least ten new business initiatives are to be seeded for the post-2030 period.

  • Non-financial targets cover emissions, safety and more women in management.

Notes on the targets:

Source: Mission 2030 Phase 2 notice and presentation (27 Feb 2026); FY3/26 Results Presentation.

ROE target: at least 8% in any year of Phase 2, by FY3/29 at the latest.

Implied record: the FY3/29 target of ¥45bn would be a record, above FY3/22's ¥40.1bn.

Shareholder returns: a cumulative 50% total return ratio over the eight-year plan, with DPS maintained or increased.

Strategic initiatives register (last 24 months)

DateInitiativeTypeDetail and targets
Sep 2024 → Mar 2026Ofuna Plant suspension and land saleFootprint rationalisationLand of 46,912 m² sold (Mar 2025 agreement); ¥8.2bn gain in FY3/26
Feb 2025 → May 2026SNECTON launch and dedicated plantNew-product platformAI/5G low-Df resin; plant done May 2026; full-swing AI sales from 2H FY3/27
Apr 2025D-NODE™ styrene chemical-recycling brandCircularityClosed-loop styrene materials
Apr 2025Revised policy on low-carbon acetylene (methane-to-acetylene) developmentDecarbonisation technologyChange in development approach (details in release)
May 2025ALSINK capacity reinforcementCapacityPower-module demand
May 2025Gosen diagnostic-reagent buildingCapacityAntigen kits
May 2025DPE production suspensionRestructuring+¥8.8bn OI (FY3/26) and +¥15.0bn (FY3/27 vs FY3/25) planned
FY3/25 onwardBest Practices Project (cost)Cost programmeP&L-factored savings: ¥0.9bn (FY3/25), ¥3.7bn (FY3/26), ¥6.8bn target (FY3/27). Total impact incl. avoided costs: ¥1.3bn, ¥5.5bn, ¥10.0bn.
Sep 2025Imerys alliance in special cement additivesPartnershipCalcium-aluminate technology; low-carbon products for Europe
Oct 2025CVC investment in a South Korean startup (thermal-conductive filler)Venture investmentHeat-dissipation fillers
Feb 2026Kainos Laboratories tender offerM&AIVD reagents; co-funded with Development Bank of Japan
Feb 2026Styrene business spin-off reviewPortfolioTarget April 2027
Mar 2026Toyo Styrene stake raised to 65%ConsolidationPrerequisite for the styrene restructuring
Jul 2026Flosonics Medical investmentDigital health CVCWearable ultrasound
Jul 2026DENKA ER exitPortfolio pruningProduction ends Aug 2028
Aug 2026Accelerated rollout of chemically recycled styrenicsCircularityMass-balance environmental value
OngoingThailand acetylene black plant (SCGC JV)CapacityPower-cable and ESS demand

Sustainability commitments

  • Carbon neutrality (Scope 1+2) by FY2050.

  • 60% reduction versus FY2013 by FY2030.

  • 150 MW maximum renewable output (KPI).

  • Zero final waste disposal.

  • Chemical-recycling consortium; "CUCO" carbon-negative concrete.

Products & Services

Pricing is generally not publicly disclosed; it is negotiated B2B, and NHI/public tender applies for vaccines. Launch years are given where disclosed.

Electronics & Innovative Products

Product lineDescription and key capabilitiesTarget customerLaunch / statusFlagship notes
SNECTON® (soft-type)Low-dielectric organic insulating resin; per Denka, the only material combining very low dissipation factor (Df) with good processability. Used as the resin component of rigid CCLs.CCL makers for AI server motherboards and IC substratesLaunched Feb 2025; dedicated plant completed May 2026; samples shipped Aug 2026Progressing toward de-facto standard in the M9-equivalent grade; M10-grade evaluations favourable; AI-related sales to ramp fully from 2H FY3/27
SNECTON (hard-type)Harder grade for different laminate architecturesCCL makersUnder development; final-stage capacity-expansion reviewBeing repositioned toward higher value-added uses after user feedback (Aug 2026)
Low-dielectric organic filler (new)Spherical, PFAS-free filler with PTFE-like low Dk (2.3) and Df (0.0006); lower CTE and specific gravity than PTFE fillersFCCL (fluorinated hybrid polyimide) and rigid-CCL makersIntroduced Aug 2026 (development)Pairs with inorganic fillers in an "organic/inorganic" materials strategy
Spherical fused silica (incl. low-Df grade)High-purity spherical SiO₂ fillers. Low-Df grade has Df ≤0.0010; Dk 3.8; CTE 0.5 ppm/°C.Resin-substrate and CCL makers; semiconductor epoxy molding compounds; optical-ferrule makersFused silica since 1971; low-Df grade in volume growthStrong AI demand; optical-ferrule demand surged in FY3/26
Spherical aluminaThermally conductive spherical Al₂O₃ fillers across particle sizes; fine powders made directly, not by sortingMolding-compound makers (GDDR7 and HBM packages), TIM makers, xEVIn production; next-generation GDDR grades in evaluationAdopted in new GPU projects and multilayer high-speed-memory packages
Acetylene black (DENKA BLACK)High-purity conductive carbon from the acetylene processHigh-voltage cable compound makers; ESS and lithium-ion battery cathode makersSince 1942; new Thailand plant (SCGC JV) under constructionPower-infrastructure demand strong; xEV demand weak in Europe; FY3/27 production constrained by Middle East feedstock
ALSINKHigh-reliability Al/SiC heat-dissipating base plate for power modulesPower-module makers (rail traction, HVDC, renewables)Capacity reinforcement announced May 2025Strong in power infrastructure and DC transmission
Silicon nitride powderSi₃N₄ powder for heat-dissipation substrates and bearing ballsCeramic-substrate and bearing makersIn productionSteady replacement demand despite weak EV market
Ceramic substrates (Si₃N₄, AlN)Insulating heat-dissipation substratesxEV and rail power-module makersIn productionPrice increases implemented; xEV weak in Europe
High-performance filmFunctional films for electronic-component processingElectronic-component makersIn productionGradual recovery
Electronic packaging / carrier tapesConductive and transparent carrier tapes for component transportComponent makers and EMSProduction in China and VietnamPart of a long-standing electronics-packaging franchise
Electronic circuit substrates ("HITT Plate")Metal-based insulated substratesLED and power-electronics makersSince 1985 (Shibukawa)—
Semiconductor process gasesMonosilane (Denar Silane), arsine (Dalian)Semiconductor fabsIn production—
Adhesives ("Hard Lock") and industrial tapes (Vinyl Tape)Structural acrylic adhesives; PVC electrical tapeIndustrial, electricalHard Lock since 1975Vinyl tape made in Vietnam
Electrical installation materialsWiring and installation productsElectrical contractors——

Life Innovation

Product lineDescriptionTarget customerStatus
Influenza HA vaccineSeasonal influenza vaccine produced in eggs (egg-price inflation is a cost factor)Japanese national immunisation and medical institutionsShipped as planned each season (manufactured for September shipment)
Rapid antigen test kits (QuickNavi™ series)Point-of-care lateral-flow tests for COVID-19, influenza and others; "combo kits" detect COVID-19 and influenza togetherClinics, hospitals, pharmaciesNew reagent manufacturing building at Gosen (Kagamida) operational May 2025; FY3/26 combo-kit shipments rose while COVID-only kits fell
IVD clinical reagentsInflammation markers and other clinical-chemistry and immunology reagentsHospital and commercial laboratories, overseas distributorsWeak in some overseas markets in FY3/26; expanded by Kainos
Kainos Laboratories reagentsClinical-diagnostic reagents developer and manufacturer (formerly DOMS-IATRON, founded 1975)LaboratoriesConsolidated from March 2026
Oncolytic virus preparationVirus-based oncology therapeutic (Denka lists it among segment products)Oncology—
Genetic point-of-care diagnostics (R&D)Simple gene-based testing systemsFuture POCTR&D at Denka Life Innovation Research (Singapore)
Cell culture ware (development)Culture vessels promoting osteogenic and adipogenic differentiation of mesenchymal stromal/stem cellsRegenerative-medicine and life-science researchersShowcased at BioJapan, 7–9 Oct 2026
Digital-health investmentsWearable electronic stethoscope (Aevice Health, Jan 2025); wireless wearable ultrasound for blood-flow assessment (Flosonics Medical, Jul 2026)—Corporate venture capital (CVC) minority stakes
ESD simulator modelEndoscopic submucosal dissection training modelMedical trainingIndustry-academia project result (Jan 2026)

Elastomers & Infrastructure Solutions

Product lineDescriptionTarget customerStatus
Chloroprene rubber (Denka Chloroprene; DPE's neoprene)Polychloroprene dry rubber and latexAutomotive belts and hoses, adhesives, wetsuits, gloves and medicalOmi only since DPE suspension (May 2025); price revision announced Apr 2026
DENKA EREthylene–vinyl acetate–acrylic ester specialty rubber (heat and oil resistant)Automotive hosesLaunched 1982; exit announced Jul 2026; production ends Aug 2028, sales end Mar 2030
Special cement additives (Denka CSA and others)Expansive and rapid-hardening additives, calcium aluminatesConcrete, infrastructure, constructionImerys technical and business alliance (Sep 2025); plants in Tianjin and Malaysia
FertilisersFused phosphate and silicate phosphate fertilisers (Hinode Chemical); humic-acid fertilisers (Denka Azumin)AgricultureOngoing
Calcium carbideFeedstock and industrial chemicalIndustrialOmi
RefractoriesHeat-resistant materialsSteel and industrial furnacesOngoing
Polyethylene corrugated pipesAgricultural and civil-engineering drainageConstruction and agricultureSales rose in FY3/26
Carbon-negative concrete "CUCO"Consortium project for CO₂-absorbing concreteConstructionR&D and consortium stage
Cement——Production ended June 2025

Polymer Solutions

Product lineDescriptionTarget customerStatus
Styrene monomerBase monomer (Chiba)Internal and externalPeriodic maintenance in FY3/27; spin-off scope
PolystyreneVia Toyo Styrene (65%)Packaging, appliancesConsolidated from 31 Mar 2026
ABS / AS resinsEngineering styrenicsAppliances, OA, automotiveVolume up in FY3/26; Middle East cuts in FY3/27
CLEAREN (SBC)Styrene-butadiene block copolymer, transparentPackaging, sheetsSingapore and Japan
MS resin / transparent resinsLight-guide plates for PC monitorsDisplay makersLosing share to Chinese products
N-phenylmaleimide heat-resistant resin (Denka IP)Heat-resistance modifier for ABSAutomotive and appliance compoundersSingapore
POVALPolyvinyl alcoholAdhesives, paper, textilesOngoing
ToyokalonSynthetic fibre for wigs and hairpiecesHair-product makers (Africa and the US)Production consolidated, delivering cost savings
Food-packaging sheets and containersStyrenic sheets and formed containers (Denka Polymer)Food retailers and processorsPrice revisions in FY3/26
Housing materialsMetal gutters and similar (Denka Astec)HousingOngoing
D-NODE™Brand for a closed-loop styrene resource-circulation (chemical recycling) systemBrand ownersLaunched Apr 2025; market rollout of recycled-content products accelerated Aug 2026

Financial Narrative

Income statement

Sources and notes: - Annual Securities Reports; FY3/25 and FY3/26 Tanshin; FY3/26 Results Presentation (operating income and depreciation series).

  • Gross profit for FY3/22–FY3/24 comes from S&P Capital IQ data via Yahoo Finance and MarketScreener. FY3/25–FY3/26 come from the Tanshin.

  • Pre-tax income was retrieved only for the latest two years (−¥17.1bn in FY3/25; +¥21.4bn in FY3/26; Tanshin).

  • Ordinary profit is the Japanese-GAAP line after non-operating items. It is shown in place of pre-tax income for the full series.

Diluted EPS equals basic because there are no dilutive shares (Annual Securities Report).

Revenue CAGR:

  • FY3/21 (¥354.4bn) to FY3/26 (¥384.2bn): +1.6% a year.

  • FY3/22 to FY3/26: ≈0.0% a year.

  • Group revenue has been essentially flat for a decade: ¥384.0bn in FY3/15 vs ¥384.2bn in FY3/26. Commodity price pass-through masks mix upgrading.

Commentary.

FY3/22 peak: Operating income reached ¥40.1bn (10.4% margin) on COVID-test demand (Life Innovation ¥15.5bn) and strong semiconductor fillers.

FY3/23–FY3/24 collapse: - Semiconductor inventory correction cut E&I operating income in half to ¥9.0bn by FY3/24.

  • Losses at the DPE chloroprene plant rose: emissions-control constraints, staffing and weather outages.

  • COVID-kit demand normalised.

  • High-cost inventory and higher fixed costs from Mission 2030 investment added pressure.

  • Gross margin fell 6.7pp between FY3/22 and FY3/24.

FY3/25 trough: Operating income was only ¥14.4bn. The DPE impairment (¥16.1bn) and ¥7.9bn liquidation losses produced a ¥12.3bn net loss and negative ROE.

FY3/26 inflection: Operating income rose 82% to ¥26.2bn on sales that fell 4%. Gross margin recovered to 24.5% from three sources:

  • E&I volume of +¥6.7bn from AI and power demand;

  • removal of DPE losses, +¥8.8bn;

  • cost cuts under the Best Practices Project (¥3.7bn of P&L-factored savings).

Net income of ¥15.7bn depended heavily on one-off gains:

  • sale of cross-shareholdings, ¥12.6bn;

  • sale of the Ofuna land, ¥8.2bn;

  • bargain-purchase gain on Toyo Styrene, ¥6.5bn.

These were offset by DPE liquidation losses (¥21.1bn) and a step-acquisition loss (¥4.9bn). Underlying recurring net income is therefore materially lower than reported.

Balance sheet

Sources and notes: - Annual Securities Report; FY3/26 Results Presentation (interest-bearing debt).

  • Owners' equity for FY3/22–FY3/24 is derived as equity ratio × total assets. FY3/25–FY3/26 are reported directly (¥296.2bn and ¥310.7bn).

Debt split (¥bn):

Source: FY3/26 Tanshin balance sheet.

Other balance-sheet items (FY3/26):

  • Goodwill ¥2.2bn (Kainos) and other intangibles ¥2.8bn, total ¥5.1bn (FY3/25: ¥3.1bn).

  • Construction in progress ¥79.0bn, up from ¥54.9bn: SNECTON, Thailand acetylene black, ALSINK.

  • Investment securities ¥47.5bn.

  • Working capital (current assets − current liabilities): ¥75.0bn, up from ¥40.0bn. The increase reflects refinancing of short-term debt into long-term borrowings, which raised the current ratio from 1.17x to 1.41x.

  • Non-controlling interests rose to ¥28.1bn from ¥12.1bn (Toyo Styrene 35% and Kainos minorities). DBJ preferred capital at Flowers also contributed to "proceeds from share issuance to non-controlling shareholders" of ¥14.2bn.

Cash flow

Sources and notes: - Annual Securities Report (cash-flow lines); FY3/26 Results Presentation (investment and lending, dividends).

  • Buybacks were zero apart from immaterial odd-lot purchases.

  • FY3/26 purchases of PP&E (cash basis) were ¥67.2bn (FY3/25: ¥58.8bn).

  • FY3/26 investing cash flow was helped by asset-sale proceeds of ¥11.3bn (PP&E) and ¥13.6bn (securities).

Denka has generated cumulative negative free cash flow of about −¥107bn over five years, financed by debt; interest-bearing debt rose by ¥85bn. FY3/23 operating cash flow collapsed to ¥8.9bn on inventory build. Management guides capex down to ¥47.0bn in FY3/27 after the FY3/25 peak (¥70.0bn), which should move free cash flow back toward break-even.

Ratios

Sources and notes: - ROE, ROIC, net D/E, DOE and total return come from the FY3/26 Results Presentation.

  • Interest coverage and Debt/OCF come from the FY3/26 Tanshin (company-defined, cash-flow based).

  • The other ratios are analyst calculations.

  • Total return for FY3/25 is not meaningful because of the net loss; it is shown as 0 for charting.

  • Accounting interest coverage (operating income / interest expense) was 12.5x in FY3/26 (¥26.2bn / ¥2.10bn) and 6.9x in FY3/25.

Cash conversion cycle (analyst calculation, year-end balances):

The roughly 160-day inventory cycle is structurally long. It reflects:

  • vaccine and diagnostic stock build for the influenza season;

  • chloroprene inventories;

  • raw-material safety stocks.

FY3/26 inventories fell ¥14.1bn in cash-flow terms, but days lengthened because cost of sales fell faster.

Trend synthesis. Every return metric bottomed in FY3/24–FY3/25 and recovered in FY3/26, but remains well below the FY3/22 level and below Denka's estimated cost of equity. Leverage has risen materially: net debt/EBITDA went from 1.8x to 3.4x. The equity ratio of 45.6% and the JCR A+ / R&I A ratings still give headroom. Financial strategy in Phase 2 depends on capex normalising and DPE cash costs ending.

Quarterly trajectory

Source: Q1 FY3/27 Results Presentation (7 Aug 2026).

Q1 FY3/27 included about ¥6.0bn of inventory gains (Polymer Solutions +¥4.8bn), which the company says may reverse. Excluding these gains, underlying Q1 operating income was about ¥5.0bn.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContents and main productsKey operating entities

Electronics & Innovative Products

Fused silica and spherical silica, spherical alumina, electronic circuit substrates, fine ceramics (silicon nitride, aluminium nitride), electronic packaging (carrier tapes), acetylene black, electrical installation materials, adhesives, adhesive tape, semiconductor process materials (monosilane, arsine), SNECTON

Parent (Omuta, Shibukawa, Isesaki, Omi); Denar Silane; Denka Advantec and Denka Singapore (SG); Denka Fine Materials Suzhou; Denka Electronic Materials Dalian; Denka Advanced Materials Vietnam; Denka SCGC (TH)

Life Innovation

Influenza vaccines, rapid-antigen diagnostic kits (QuickNavi), clinical IVD reagents, oncolytic virus preparation

Parent (Gosen/Kagamida sites); Kainos Laboratories (from Mar 2026); Denka Life Innovation Research (SG); Icon Genetics (DE)

Elastomers & Infrastructure Solutions

Chloroprene rubber, DENKA ER (exit announced), fertilisers, calcium carbide, refractories, special cement additives, polyethylene corrugated pipes

Parent (Omi, Chiba); DPE (US, suspended); Hinode Chemical; Denka Azumin; Denka Inorganic Materials Tianjin; Denka Infrastructure Malaysia

Polymer Solutions

Styrene monomer, ABS, AS, SBC (CLEAREN), N-phenylmaleimide heat-resistant resin, transparent and MS resins, POVAL, Toyokalon wig fibre, food-packaging sheets and containers

Parent (Chiba); Toyo Styrene (65% from 31 Mar 2026); Denka Polymer; Denka Astec; Denka Singapore; Denka Advantec; Denac (affiliate)

Others

Plant engineering, trading/wholesale (Akros Trading / YK Acros), power supply (Kurobegawa Electric Power, affiliate)

Denka Engineering; Akros Trading

Segment net sales (JPY Bn)

Segment net sales (JPY Bn)FY3/24FY3/25FY3/26FY3/27F

Electronics & Innovative Products

87.892.2104.4110.0

Life Innovation

47.143.340.545.0

Elastomers & Infrastructure Solutions

111.4111.797.6105.0

Polymer Solutions

124.2135.4124.2170.0

Others

18.817.717.620.0

Total

389.3400.3384.2450.0

Segment operating income (JPY Bn)

Segment operating income (JPY Bn)FY3/20FY3/21FY3/22FY3/23FY3/24FY3/25FY3/26FY3/27F

Electronics & Innovative Products

12.714.218.718.09.09.213.913.0

Life Innovation

7.014.815.514.411.79.66.26.0

Elastomers & Infrastructure Solutions

3.9-3.6-3.5-1.1-9.3-8.00.17.0

Polymer Solutions

7.18.47.9-1.2-0.11.23.62.0

Consolidated operating income

31.634.740.132.313.414.426.230.0

Segment Overview — E&I

SegmentSales JPY BnYoY sales %OI JPY BnYoY OI JPY BnOI margin %% of group salesSegment assets JPY BnDepreciation JPY Bn

E&I

104.4+13.313.9+4.713.327.2255.611.2

Life Innovation

40.5-6.36.2-3.415.410.572.34.2

E&IS

97.6-12.60.07+8.00.125.4145.58.3

Polymer Solutions

124.2-8.33.6+2.42.932.3119.65.2

Others

17.6-1.12.40.013.84.648.80.4

Group

384.2-4.026.2+11.86.8100.0681.029.2

Segment ROIC (%)

Segment ROIC (%)FY3/22FY3/23FY3/24FY3/25FY3/26FY3/27F

Electronics & Innovative Products

14.712.15.44.55.74.8

Life Innovation

17.815.313.810.86.66.0

Elastomers & Infrastructure Solutions

-2.5-0.3-5.4-4.90.35.5

Polymer Solutions

9.6-1.30.01.63.32.3

Consolidated

7.36.72.52.54.24.5

Financial Analysis

Metric (JPY Bn)FY3/22FY3/23FY3/24FY3/25FY3/26

Net sales

384.8407.6389.3400.3384.2

Gross profit

107.2102.382.584.694.3

Operating income

40.132.313.414.426.2

Depreciation

23.927.026.927.929.2

EBITDA (OI + depreciation)

64.059.340.342.355.4

Ordinary profit

36.528.05.57.619.3

Net income attributable to owners

26.012.811.9-12.315.7

Comprehensive income

31.720.919.3-7.119.1

Total assets

557.6592.2616.2655.5681.0

Cash and equivalents

20.220.235.437.035.3

Interest-bearing debt total

137.0169.7174.4217.7221.7

Net debt

116.8149.5139.0180.7186.4

Shareholders' equity (owners)

288.3296.7307.5296.2310.7

Total net assets (incl. NCI)

292.1300.4316.9308.3338.8

Equity ratio (%)

51.750.149.945.245.6

Operating cash flow

42.68.936.318.636.2

Investing cash flow

-36.8-28.3-22.6-59.6-45.0

Capex (investment and lending, company basis)

35.639.444.070.060.8

Free cash flow (OCF − capex)

7.0-30.5-7.7-51.4-24.6

Financing cash flow

-12.318.40.740.17.6

Dividends declared (total)

12.58.68.68.68.6

Share buybacks

00000

Per share (JPY)

Per share (JPY)FY3/22FY3/23FY3/24FY3/25FY3/26

EPS basic

301.67148.08138.61-142.73182.10

EPS diluted

301.67148.08138.61-142.73182.10

Dividend per share

145100100100100

Book value per share

3,345.343,438.283,568.693,436.953,604.53

Margins (%)

Margins (%)FY3/22FY3/23FY3/24FY3/25FY3/26

Gross margin

27.925.121.221.124.5

Operating margin

10.47.93.43.66.8

EBITDA margin

16.614.510.410.614.4

Net margin

6.83.13.1-3.14.1

Debt composition (JPY Bn)

Debt composition (JPY Bn)FY3/25FY3/26

Short-term borrowings

74.751.8

Commercial paper

33.020.0

Current portion of bonds

15.015.0

Current portion of long-term borrowings

0.00.2

Short-term debt subtotal

122.787.0

Bonds (non-current)

15.010.0

Long-term borrowings

80.0124.8

Long-term debt subtotal

95.0134.8

Financial Analysis — ROE

RatioFY3/22FY3/23FY3/24FY3/25FY3/26

ROE (%)

9.44.44.0-4.15.2

ROA, net income / year-end total assets (%)

4.72.21.9-1.92.3

ROIC, company basis (%)

7.36.72.52.54.2

Gross debt / equity (x)

0.480.570.570.730.71

Net D/E, company basis (x)

0.400.500.450.610.60

Net debt / EBITDA (x)

1.82.53.44.33.4

Interest coverage, OCF / interest paid (x)

45.48.121.78.917.7

Debt / OCF (years)

3.219.04.811.76.1

Asset turnover, sales / year-end assets (x)

0.690.690.630.610.56

Dividend on equity, DOE (%)

4.52.92.92.92.8

Total return ratio (%)

486872055

Financial Analysis — DSO

Metric (days)FY3/25FY3/26

DSO (receivables / sales × 365)

8084

DIO (inventory / COGS × 365)

151160

DPO (payables / COGS × 365)

5654

Cash conversion cycle

176190

Revenue History

QuarterNet salesOperating incomeOI margin %

Q1 FY3/25

95.24.74.9

Q2 FY3/25

103.84.74.5

Q3 FY3/25

102.52.42.3

Q4 FY3/25

98.72.62.6

Q1 FY3/26

94.12.32.4

Q2 FY3/26

102.67.47.2

Q3 FY3/26

94.18.59.0

Q4 FY3/26

93.58.08.6

Q1 FY3/27

97.011.011.3

Q2 FY3/27F

108.06.05.6

Region net sales (JPY Bn)

Region net sales (JPY Bn)FY3/24FY3/25FY3/26

Japan

226.2221.7214.3

Asia (ex-Japan)

98.0114.4106.0

Other regions (Americas, Europe, other)

65.164.263.9

Total

389.3400.3384.2

Region share and growth (%)

FY3/24

FY3/25

FY3/26

Japan share

58.155.455.8

Asia share

25.228.627.6

Other share

16.716.016.6

Overseas share total

41.944.644.2

Japan YoY growth

—-2.0-3.3

Asia YoY growth

—16.8-7.3

Other YoY growth

—-1.4-0.4

Annual Price Range Details

Annual price range (JPY)FY3/22FY3/23FY3/24FY3/25FY3/26

High

4,5353,6202,9092,3843,750

Low

3,1902,5102,3431,7171,744

5-year TSR index (Mar 2021 = 100)

FY3/22

FY3/23

FY3/24

FY3/25

FY3/26

Denka TSR

80.267.460.958.492.2

Nikkei 225 Total Return

97.2100.2147.0132.2192.9

Valuation Multiples

MultipleDenka

P/E, trailing (FY3/26 EPS ¥182.10)

≈17.6x (Yahoo: 17.7x)

P/E, forward (FY3/27 guided EPS ¥185.67)

≈17.2x

P/B (BPS ¥3,604.53)

≈0.89x

EV (market cap + net debt ¥186.4bn + NCI ¥28.1bn)

≈¥495bn

EV/EBITDA (FY3/26 EBITDA ¥55.4bn)

≈8.9x

EV/Sales (FY3/26)

≈1.29x

Dividend yield (¥100)

≈3.1%

Capital Markets

ItemValueSource

Average target price

¥4,502.5 (high ¥5,300; low ¥3,160)

Yahoo Finance, Sep–Oct 2026

TradingView range

Max ¥5,300; min ¥4,000

Jul 2026

Consensus next-year EPS

¥171

Stockopedia, Apr 2026

Q1 FY3/27 operating income consensus

¥5.6bn (actual ¥11.0bn)

Bloomberg via Investing.com

Dividend metric

Dividend metricFY3/22FY3/23FY3/24FY3/25FY3/26FY3/27F

DPS (JPY)

145100100100100100

Total dividends (JPY Bn)

12.58.68.68.68.68.6

Payout ratio consolidated (%)

48687205554

Credit Ratings

AgencyLong-termOutlookShort-termLatest action

JCR

A+

Stable

J-1

New bond rated A+ (3 Jul 2026); shelf A+ (10 Apr 2026)

R&I

A

Stable

a-1

Affirmed 22 Sep 2025; shelf preliminary A (10 Apr 2026)

Moody's / S&P / Fitch

Not rated

———

Analyst Conclusions

Management guidance (FY3/27, as of 7 Aug 2026)

Item1H FY3/27 revisedFull year FY3/27 (unchanged)
Net sales¥205.0bn¥450.0bn
Operating income¥17.0bn (from ¥12.0bn)¥30.0bn
Ordinary profit¥11.0bn¥20.0bn
Net income¥0.0bn¥16.0bn (EPS ¥185.67)
Assumptions¥160.4/USD; naphtha ¥99,300/kl¥158/USD; naphtha ¥123,250/kl

Management expects to review full-year guidance with 1H results on 9 November 2026. The main risks it flags are reversal of inventory gains and Middle East and feedstock uncertainty.

Implied 2H operating income is only ¥13.0bn (¥30.0bn − ¥17.0bn), versus 2H FY3/26's ¥16.5bn. This looks conservative if feedstock normalises.

Bull case

  1. AI materials re-rate E&I. SNECTON's full-swing AI sales from 2H FY3/27, continued low-Df silica and GDDR/HBM alumina growth, and the new organic filler could take E&I operating income back toward its FY3/22 peak of ¥18.7bn by FY3/29. Segment ROIC could recover from 5.7% to above 10%. Q1 FY3/27 E&I operating income was already ¥3.7bn (+48% YoY).

  2. Self-help is largely in hand. DPE removal adds +¥15.0bn versus FY3/25 by FY3/27. Best Practices savings rise to ¥6.8bn. E&IS swings from −¥8.0bn (FY3/25) to +¥7.0bn guidance (FY3/27). This visible, non-market-dependent profit bridge supports the Phase 2 path to ¥45bn operating income and ROE of at least 8%.

  3. Portfolio simplification unlocks value. A styrene spin-off by April 2027 would move about a third of sales (PS ¥124bn, 2.9% margin) out of the core. Higher group margins and lower capex intensity could close the P/B discount (0.89x). Capex falling from ¥70bn to ¥47bn should turn free cash flow positive.

Bear case

  1. Earnings quality is weak. FY3/26 net income relied on about ¥27bn of one-off gains. Q1 FY3/27 operating income included ¥6.0bn of inventory gains that management warns may reverse. DPE extraordinary losses continue (¥4.8bn in Q1). Net income of ¥16bn in FY3/27 implies ROE of only about 5%, far from 8%.

  2. Balance-sheet stretch and negative free cash flow. Five-year cumulative free cash flow is about −¥107bn. Net debt/EBITDA is 3.4x. Dividends of ¥8.6bn a year are not covered by free cash flow. Any AI-cycle pause or prolonged Middle East disruption could force a choice between the dividend and capex.

  3. Legacy and cyclical drag persists. Chloroprene is in structural decline (230 kt global demand). Life Innovation operating income fell to ¥6.2bn and 1H guidance was cut again. Styrenics face Chinese competition. The five-year TSR of −7.8% against +92.9% for the Nikkei TR shows repeated failure to deliver on plans (the original Mission 2030 targets were abandoned).

Catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
9 Nov 20261H FY3/27 results; full-year guidance review; size of inventory-effect reversal
2H FY3/27SNECTON AI-volume ramp; hard-type SNECTON capacity decision; low-Df filler adoption
OngoingMiddle East feedstock normalisation (assumed from October 2026); naphtha price path
By early FY3/28DPE closure plan; final exit costs; Mitsui cost sharing; any residual US litigation
By Apr 2027Styrene spin-off structure (scope, partners, Toyo Styrene role)
Winter 2026/27Influenza and COVID season, which drives antigen-kit demand
OngoingKainos integration; possible minority squeeze-out
May 2027FY3/27 results; FY3/28 guidance against the Phase 2 plan (operating income ¥40bn)
Jun 2027AGM votes on directors (ISS/ROE screen); board-independence refresh
OngoingThailand acetylene black plant start-up; ALSINK capacity

Analyst verdict

Denka is a company in transition whose investment case now rests on whether a genuinely differentiated AI- and power-materials franchise can outgrow a large and still-volatile legacy base. FY3/26 marked a real operational inflection: operating income almost doubled to ¥26.2bn on sales that fell 4%. Three things drove it: AI-related E&I volume, the decisive suspension of the loss-making US chloroprene plant, and measurable cost cuts. Q1 FY3/27 extended that trend to an 11.3% operating margin, the highest in years.

Several factors argue against extrapolating that run-rate:

  • Reported profits still carry heavy one-off items in both directions.

  • The Q1 beat was roughly half inventory gains that management expects may reverse.

  • Free cash flow has been negative for four of the last five years, and leverage has risen to 3.4x net debt/EBITDA.

  • Management's credibility is partly rebuilt but not restored. The original Mission 2030 targets of ¥100bn operating income and ROE of 15% have effectively been replaced by more modest Phase 2 goals, and proxy advisers have challenged the leadership's returns record.

The equity at about ¥3,200 trades below book (0.89x P/B) and at about 17x guided earnings. On normalised earnings this is not demanding if Phase 2's ¥40–45bn operating income is achieved, but it is not distressed either. The consensus target of about ¥4,500 implies the market is giving partial credit. Upside in the share price depends on three things that are within management's control and verifiable within 12 months:

  1. clean execution of the DPE closure without new liabilities;

  2. a credible styrene separation by April 2027;

  3. visible SNECTON and low-Df revenue scaling in 2H FY3/27.

Verdict: a constructive but execution-dependent "show-me" story. The quality of the AI-materials franchise justifies close monitoring and selective accumulation on drawdowns. Conviction should be sized against the balance-sheet and earnings-quality risks until free cash flow turns sustainably positive and ROE reaches at least 7%.


Source notes

Denka primary documents: - 167th Annual Securities Report (17 Jun 2026)

  • FY3/26 Consolidated Financial Results (13 May 2026)

  • FY3/26 Results Presentation (13 May 2026) and script

  • Q1 FY3/27 Results Presentation (7 Aug 2026)

  • Mission 2030 Phase 2 notice and presentation (27 Feb 2026)

  • Styrene spin-off notice (27 Feb 2026)

  • DENKA ER withdrawal (17 Jul 2026)

  • Extraordinary-loss notice (7 Aug 2026)

  • Imerys alliance release (1 Sep 2025)

  • ISS response (2 Jun 2025)

  • Ofuna asset-sale notice (28 Mar 2025)

  • Toyo Styrene consolidation notice (9 Mar 2026)

  • Kainos tender offer notices (Feb–Mar 2026)

  • Company website: officers (1 Apr 2026); shareholder data (31 Mar 2026); news lists 2025–2026

  • Denka Sustainability Site

Third-party sources: - US EPA (RCRA settlement summary)

  • Fox8, Manufacturing Dive, Rubber News, C&EN, Chemistry World, European Rubber Journal (DPE coverage)

  • DuPont 10-Q (FY2025)

  • JCR and R&I rating pages

  • Yahoo Finance, StockAnalysis, Stockopedia, TradingView (market data)

  • MarketScreener / S&P Capital IQ (gross profit, R&D history)

  • Investing.com (Q1 FY3/27 consensus)

  • Tosoh FY3/26 results; Resonac FY2025 results; The Shashi (Daicel comparison)

  • Kabutan and gBizINFO (shareholders, auditor)

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NamePositionIndependent?Born / age (Oct 2026)Joined boardBackground

Toshio Imai

Chairman & Representative Director

No (former CEO)

25 Jan 1959 / 67

Director since Jun 2019

Joined 1982; styrene and elastomer businesses; Corporate Planning GM; President & CEO Apr 2021 – Mar 2025

Ikuo Ishida

Representative Director, President & CEO

No

7 Mar 1962 / 64

Director since Jun 2023

Joined 1985; career in electronics materials (functional films, advanced fillers, specialty materials); E&I division GM from 2019; CEO since Apr 2025

Rimiru Hayashida

Director, Senior Managing Executive Officer; CFO & CSCO

No

—

Jun 2025

Joined 1985; Accounting GM; CFO since Jun 2024

Masanobu Kosaka

Director, Managing Executive Officer; CTO

No

—

Jun 2025

Joined 1985; Omi Plant GM; former Vice President of DPE

Rumiko Nakata

Outside Director

Yes

—

Jun 2024

Esso; Pfizer Japan HR corporate officer; Mitsubishi Chemical director (HR, D&I); outside director at Kyowa Kirin

Mizuhiro Uchida

Director (full-time Audit & Supervisory Committee member)

No

24 Sep 1961 / 65

Jun 2023

Internal audit and internal control at Denka

Toshio Kinoshita

Outside Director (ASC member)

Yes

12 Apr 1949 / 77

Outside auditor 2015; outside director since 2019

CPA; PwC North America senior managing partner; former JICPA chief executive; former outside roles at Panasonic and Mizuho Bank

Akio Yamamoto

Outside Director (ASC member)

Yes, but ex-Mitsui & Co., which is DPE's 30% partner and a shareholder

2 Dec 1951 / 74

Jun 2015

Mitsui & Co. executive officer; President of Mitsui Bussan Plastic Trade

Miyuki Matoba

Outside Director (ASC member)

Yes

15 Aug 1973 / 53

Jun 2021

Lawyer; former Japan Federation of Bar Associations executive governor; legal and compliance at MOS Food Services and Nitto Kohki

“—” = not publicly disclosed.

Executive Leadership Team

NameRole

Ikuo Ishida

President & CEO

Rimiru Hayashida

Senior MEO; CFO, CSCO; Accounting, Finance, Corporate Communications, Purchasing, Logistics

Masanobu Kosaka

MEO; CTO; Production Engineering, New Business Development, Technology Planning, Sustainability Promotion, Digital Strategy & Innovation

Kei Hara

MEO; CHRO, CCO; Corporate Planning, Best Practice Promoting, HR, Denka Corporation (US), Denka Chemicals GmbH, China business

Hiroto Horiuchi

MEO; President, Akros Trading

Michio Kawamura

MEO; Omi Plant

Masahiro Kawai

EO; Managing Director, DCHA / DSPL / DAPL (Singapore)

Takeshi Hagiwara

EO; Omuta Plant

Masahiro Omata

EO; Polymer Solutions

Tetsuo Noguchi

EO; Gosen site

Koji Nishimura

EO; Production Engineering

Taro Inada

EO; Life Innovation (also Representative Director of Flowers Co., the Kainos acquisition vehicle)

Akinori Adachi

EO; Administrative, Legal, Secretary, Internal Control

Hiromichi Awada

EO; Chiba Plant

Akira Kasahara

EO; GM Accounting

Koya Takahashi

EO; Elastomers & Infrastructure Solutions

Masahide Yamada

EO; New Business Development

Tomoya Kowada

EO; Electronics & Innovative Products

Jun Nakamoto

EO; President, DPE

Osamu Kunitomo

EO; Shibukawa Plant

Board & Management Changes

DateChangeContext

7 Feb 2025 (effective Apr 2025)

Ishida succeeds Imai as President & CEO; Imai becomes Chairman

Handover to an electronics-materials leader amid the DPE crisis

Jun 2025

Hayashida (CFO) and Kosaka (CTO) join the board

Board refresh

Jun 2025 AGM

ISS recommends voting AGAINST Imai and Ishida because 5-year average ROE is below 5%; company publicly rebuts

Shareholder-pressure signal

26 Dec 2025; 6 Feb 2026

Executive officer reshuffles

Alignment with Phase 2

Jun 2026

167th AGM

—

Major Shareholders

RankHolderShares (100s)%
1

The Master Trust Bank of Japan (trust account)

157,57518.27
2

Custody Bank of Japan (trust account)

110,85412.85
3

Mizuho Trust & Banking — retirement benefit trust, Mizuho Bank account

32,1583.73
4

State Street Bank and Trust Co. 505001

26,7403.10
5

Taiju Life Insurance

23,8162.76
6

Nomura Trust & Banking (investment trust account)

21,7802.52
7

Custody Bank of Japan (trust account 4)

19,6242.27
8

State Street Bank and Trust Co. 505223

15,8591.84
9

Denka Employee Shareholding Association

15,8281.83
10

JP Morgan Securities Japan

12,6731.47

Competitive Landscape

Competitors by Segment

Segment / productKey competitorsDenka's relative position

Spherical silica and alumina fillers

Admatechs (Toyota group); Nippon Steel Chemical & Material (Micron); Tatsumori; Chinese suppliers

One of the leading global suppliers of spherical fused silica; strong in fine and high-purity grades; well placed in AI substrates

Low-dielectric resins (SNECTON)

SABIC (PPE-based low-Df resins); Asahi Kasei (PPE); Mitsubishi Gas Chemical

New entrant with a differentiated processability claim; certified at multiple CCL makers

Acetylene black and conductive carbon

Orion Engineered Carbons; Cabot; Imerys Graphite & Carbon; Lion Specialty Chemicals (Ketjenblack); Chinese acetylene black makers

High purity from the carbide route; leader in HV-cable grades; pressured by Chinese supply in batteries

Ceramic substrates and Si₃N₄

Toshiba Materials; Kyocera; Maruwa; UBE (Si₃N₄ powder); Rogers (curamik)

Integrated from powder to substrate

AlSiC (ALSINK)

Niche Western and Asian suppliers

Strong in rail and HVDC

Chloroprene rubber

Tosoh (Skyprene); Arlanxeo (Baypren); Chinese producers

Remains among the top global producers via Omi after DPE; market declining (about 230 kt a year)

Special cement additives

Sika; Imerys (now also a partner); Taiheiyo Materials; Chinese producers

Japanese leader in CSA expansive additives

Influenza vaccine (Japan)

BIKEN; KM Biologics; Daiichi Sankyo Biotech

One of a small number of domestic producers

Rapid antigen and IVD

Fujirebio (H.U. Group); Sekisui Medical; Abbott; Roche; Fujifilm; Tauns

Strong POCT brand in Japan; small globally

Styrenics (SM, ABS, PS, SBC, MS)

PS Japan (Asahi Kasei / Idemitsu / Mitsui Chemicals); Techno-UMG; Toray (ABS); Chi Mei; LG Chem; INEOS Styrolution; Chinese producers

Sub-scale; losing MS share to China; spin-off review

Wig fibre (Toyokalon)

Kaneka (Kanekalon); Chinese PVC-fibre makers

Second global brand behind Kaneka (analyst view)

Diversified Japanese chemical peers (corporate level)

Tosoh; Resonac; Daicel; Shin-Etsu Chemical; Sumitomo Bakelite

Smaller, more diversified, lower margin than specialty leaders

Peer Comparison

Company (latest FY)Revenue JPY BnRevenue growth %Operating margin %Net income JPY BnR&D intensity %

Denka (FY3/26)

384.2-4.06.815.73.9

Tosoh (FY3/26)

1,019.9-4.19.441.6—

Resonac (FY12/25, IFRS)

1,347.1-3.2

8.1 (core); 3.5 (IFRS)

29.0—

Daicel (FY3/26)

about 580

—7.3——

Recent Developments

--

Company Snapshot

6,358

Employees

1915

Founded

Tokyo, Japan

Headquarters

SWOT Analysis

Strengths

  • AI-materials momentum. E&I sales rose 13.3% to ¥104.4bn and operating income rose 51.5% to ¥13.9bn in FY3/26, driven by spherical silica, spherical alumina and SNECTON (FY3/26 Tanshin).
  • Unique low-Df portfolio. SNECTON plant completed May 2026. The company reports steady progress toward de-facto standard in M9-equivalent CCL grades, with favourable M10 evaluations (Q1 FY3/27 presentation).
  • Power-infrastructure exposure. Acetylene black (HV cables, ESS) and ALSINK (HVDC, rail) both cited as strong in FY3/26–Q1 FY3/27.
  • Investment-grade balance sheet. JCR A+/Stable and R&I A/Stable; equity ratio 45.6% (Mar 2026).
  • Demonstrated restructuring execution. DPE suspension delivered +¥8.8bn operating income in FY3/26 in line with the ¥9bn plan. Best Practices savings of ¥3.7bn in FY3/26.
  • Vertical integration and low-carbon power. In-house hydroelectricity at Omi. Scope 1+2 emissions already 72% below FY2013 (FY3/25), well ahead of the 60% FY2030 target.
  • Healthcare franchise. Domestic influenza-vaccine supplier; Kainos adds IVD scale; Life Innovation operating margin 15.4% even at a cyclical low.

Weaknesses

  • Low returns. ROE averaged under 5% over FY3/22–FY3/26 (9.4, 4.4, 4.0, −4.1, 5.2). ROIC of 4.2% in FY3/26.
  • Persistent negative free cash flow. Cumulative OCF − capex of about −¥107bn over five years. Net debt rose from ¥116.8bn to ¥186.4bn.
  • Leverage. Net debt/EBITDA 3.4x (FY3/26) vs 1.8x (FY3/22).
  • Earnings quality. FY3/26 net income included ¥27.3bn of one-off gains (securities ¥12.6bn, land ¥8.2bn, bargain purchase ¥6.5bn) against ¥26.0bn of extraordinary losses.
  • Commodity mix. PS and E&IS made up 57.7% of FY3/26 sales but only 14% of segment operating income.
  • Long working-capital cycle. About 190 days CCC (FY3/26), with inventory days around 160.
  • No revenue growth. Ten-year sales roughly flat (¥384.0bn FY3/15 vs ¥384.2bn FY3/26).

Opportunities

  • AI-substrate ramp. Full-swing SNECTON AI sales expected from 2H FY3/27; hard-type expansion under final review.
  • Styrene spin-off by April 2027. Could raise group margins and ROIC and open capital partnerships (27 Feb 2026 notice).
  • Phase 2 profit path. Operating income from ¥30bn (FY3/27F) to ¥45bn (FY3/29 plan), which would be a record.
  • European low-carbon construction through the Imerys alliance (Sep 2025).
  • Thailand acetylene black capacity for ESS and HV cable demand.
  • Chloroprene pricing. Omi supplies former DPE customers; price revision April 2026.
  • ESG index inclusion. FTSE Blossom inclusion (Jul 2026) and CDP Climate A− could broaden the shareholder base.

Threats

  • Middle East supply shock. FY3/27 guidance includes −¥5.0bn. Naphtha assumption ¥123,250/kl vs ¥65,800/kl in FY3/26. Acetylene black output cut.
  • Inventory-gain reversal. Q1 FY3/27's +¥6.0bn could turn negative if feedstock prices fall (company caution, Aug 2026).
  • Continuing DPE exit costs. ¥4.8bn in Q1 FY3/27; more extraordinary losses expected; US environmental liabilities (RCRA settlement Jul 2026; private litigation risk).
  • Infection-driven diagnostics volatility. 1H FY3/27 Life Innovation operating income guidance cut by ¥2.0bn; market inventory clearing slowly.
  • Chinese competition in MS resin, styrenics and battery carbons (company commentary FY3/26–Q1 FY3/27).
  • Governance and activism pressure. ISS voted against the top two executives in 2025 on ROE grounds. TSE pressure on below-book valuations (P/B about 0.9x).
  • AI capex cyclicality or design changes in CCL and package materials.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Ishida becomes CEO; Imai becomes ChairmanLeadership transition
7 Apr 2025D-NODE™ styrene circulation brand; revised low-carbon acetylene policySustainability positioning
21 Apr 2025Ofuna land transfer completes¥8.2bn gain recorded in FY3/26
13 May 2025FY3/25 results: net loss ¥12.3bn; DPE impairment ¥16.1bn; executives return part of payTrough year
13 May 2025DPE suspends chloroprene production indefinitely; sale also consideredMajor restructuring decision
13 May 2025ALSINK capacity reinforcementPower-module growth
20 May 2025Gosen reagent manufacturing building operationalDiagnostics capacity
30 May 2025Management presentation (pre-revision)Signals plan review
2 Jun 2025Company rebuts ISS "against" recommendation on Imai and Ishida over ROEGovernance pressure
Jun 2025Cement production ends at OmiCommodity exit complete
7 Aug 2025Q1 FY3/26: operating income ¥2.3bn (−51% YoY)Weak start to the recovery year
1 Sep 2025Imerys alliance (special cement additives)European growth route
17 Oct 2025CVC investment in Korean thermal-filler startupThermal-management pipeline
10 Nov 20251H FY3/26 results; extraordinary DPE losses; outline of plan revisionEarnings recovery visible (Q2 OI ¥7.4bn)
27 Nov 2025New bond issue rated A+ by JCRFunding
26 Dec 2025Executive officer changes—
16 Jan 2026CDP 2025: Climate A−, Water AESG upgrade (from B in Climate)
6 Feb 2026Q3 FY3/26 results; full-year sales guidance cut to ¥390bn, OI kept at ¥25bn; Kainos tender offer announced (¥2,285/share)Healthcare M&A
19 Feb 2026Selected at ESG Finance Awards Japan (Environmentally Sustainable Company)ESG recognition
27 Feb 2026Mission 2030 Phase 2 (ROE ≥8%; OI ¥35bn → ¥45bn); styrene spin-off review (target Apr 2027)Strategic reset
9 Mar 2026Toyo Styrene to become consolidated (buys Daicel's 15%)Styrenics control
10 Mar 2026White 500 health-management recognition (4th year)Human capital
26 Mar 2026Kainos tender offer result (77.65%); gain on sale of investment securities announcedDeal closed; ¥12.6bn gain
10 Apr 2026R&I preliminary A on shelf registration; JCR A+ on shelfFunding capacity
20 Apr 2026Chloroprene price revisionPricing power after DPE supply exit
13 May 2026FY3/26 results: OI ¥26.2bn (+82%), NI ¥15.7bn; FY3/27 guidance OI ¥30bn including −¥5bn Middle East impactV-shaped recovery; supply shock factored in
18 May 2026SNECTON dedicated plant completedAI growth capacity
10 Jun 2026CDP Supplier Engagement rating "A" (first time)ESG
19 Jun 2026167th AGM held; DPS ¥100 approvedGovernance
2 Jul 2026US EPA RCRA settlement with DPE: US$996,703 penalty, waste-handling upgradesLegacy regulatory cost
3 Jul 2026New bond (JCR A+)Funding
9 Jul 2026First inclusion in two FTSE JPX Blossom ESG indices; Flosonics Medical investmentESG index demand; digital health
17 Jul 2026Exit from DENKA ER specialty rubber (production ends Aug 2028)Portfolio pruning
7 Aug 2026Q1 FY3/27: OI ¥11.0bn (+378% YoY; Bloomberg consensus was about ¥5.6bn); NI ¥2.8bn after ¥4.8bn DPE loss; 1H OI guidance raised to ¥17.0bn from ¥12.0bn; full-year kept at ¥30.0bnBig beat, partly inventory-driven (+¥6.0bn)
20 Aug 2026Former Ofuna site soil-contamination investigation results disclosedEnvironmental liability monitoring (details in release)
26 Aug 2026Accelerated rollout of chemically recycled styrenicsCircularity
29 Sep 2026Ex-dividend date for ¥50 interim—
1 Oct 2026Cell culture ware showcased at BioJapan 2026 (7–9 Oct)New-business pipeline
9 Nov 2026 (scheduled)1H FY3/27 results; full-year guidance review promisedKey catalyst

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.